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ABSTRACT
Modern molecular imaging techniques have greatly improved tumor detection 
and post-treatment follow-up of cancer patients. In this context, antibody-based 
imaging is rapidly becoming the gold standard, since it combines the unique specificity 
of antibodies with the sensitivity of the different imaging technologies. The aim of this 
study was to generate and characterize antibodies in single chain Fragment variable 
(scFv) format directed to an emerging cancer biomarker, the human ether-à-go-go-
related gene-1 (hERG1) potassium channel, and to obtain a proof of concept for their 
potential use for in vivo molecular imaging.
The anti-hERG1scFv was generated from a full length monoclonal antibody and 
then mutagenized, substituting a Phenylalanine residue in the third framework of the 
VH domain with a Cysteine residue. The resulting scFv-hERG1-Cys showed much higher 
stability and protein yield, increased affinity and more advantageous binding kinetics, 
compared to the “native” anti-hERG1scFv. The scFv-hERG1-Cys was hence chosen and 
characterized: it showed a good binding to the native hERG1 antigen expressed on 
cells, was stable in serum and displayed a fast pharmacokinetic profile once injected 
intravenously in nude mice. The calculated half-life was 3.1 hours and no general 
toxicity or cardiac toxic effects were detected. Finally, the in vivo distribution of 
an Alexa Fluor 750 conjugated scFv-hERG1-Cys was evaluated both in healthy and 
tumor-bearing nude mice, showing a good tumor-to-organ ratio, ideal for visualizing 
hERG1-expressing tumor masses in vivo.
In conclusion, the scFv-hERG1-Cys possesses features which make it a suitable 
tool for application in cancer molecular imaging. 
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INTRODUCTION
Molecular imaging techniques are continuously 
progressing, allowing non-invasive in vivo visualization 
of biological and pathological processes at the molecular 
and cellular levels. These methods are particularly suitable 
for application in oncology, where the improvement 
of available technologies has been paralleled by the 
development of targeting agents that can assure the high 
selectivity necessary for appropriate cancer diagnostics. 
Antibody-based imaging is becoming the gold standard 
in this field, since the combination of different imaging 
methodologies with tumor specificity has the potential 
to greatly improve cancer diagnosis and therapy follow 
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up [1–5]. However, intact monoclonal antibodies (mAbs) 
are large (150 kDa) molecules, with generally slow 
pharmacokinetics, slow blood clearance, sub optimal 
tumor penetration and accumulation, and are often 
difficult to produce [6]. These characteristics can delay the 
time point for imaging, and often results in sub-optimal 
contrast between the tumor mass and the surrounding 
normal tissue. Antibodies in the single chain Fragment 
variable (scFv) format seem the optimal candidates to 
overcome such hindrances. A scFv antibody consists of 
variable regions of heavy (VH) and light (VL) chains (i.e. 
the smallest unit of an immunoglobulin molecule which 
binds its specific antigen), joined together by a flexible 
peptide linker. The reduced size (usually 25–30 kDa) of 
scFv antibodies speeds up their penetration into tissues 
and enhances their clearance from the blood, thus making 
scFv antibodies preferred tools for in vivo diagnostic 
purposes [7]. Moreover, scFv antibodies can be often 
easily expressed in functional form in E. coli or yeasts, 
facilitating protein engineering to further increase the 
affinity or modify the specificity [8]. Finally, it is possible 
to conjugate the recombinant proteins with quantum dot, 
fluorescent dyes or other moieties, hence potentiating their 
exploitability for in vivo imaging. For these reasons, scFv 
antibodies are becoming the ideal candidates in imaging 
applications, especially for cancer diagnostics [2–5].
The huge amount of work aimed at the identification 
of novel cancer biomarkers suitable for both therapeutic 
and diagnostic purposes, has recently led to consider 
plasma membrane proteins devoted to ion transport as 
good candidates for targeting cancer cells both in vitro 
and in vivo [9]. Indeed, ion channels and transporters are 
frequently over-expressed in cancers cells, hence behaving 
as novel cancer associated antigens. What is more, ion 
channels and transporters are easily accessible due to 
their expression on the plasma membrane [10]. Although 
technically challenging due to the limited availability of 
antigenic extracellular epitopes in this class of membrane 
proteins [11], both full length and scFv antibodies have 
been recently developed against those ion channels and 
transporters over- or mis-expressed in human cancers. 
For example, a scFv against Kv 10.1 (EAG1), a member 
of the ether-à-go-go (EAG) family of potassium channels 
frequently expressed in human cancers, has been raised 
and fused to the human soluble tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL), showing a 
selective pro-apoptotic activity on Kv 10.1 positive cancer 
cells [12]. Another member of the same family, Kv 11.1 
(hERG1), besides being highly expressed in human cardiac 
myocytes, where it constitutes the molecular correlate of 
the repolarizing current IKr, is often over-expressed in 
human cancers [13]. In cancer, hERG1 regulates different 
aspects of neoplastic progression (i.e. cell proliferation and 
survival, cell invasiveness and angiogenesis), and behaves 
as a powerful diagnostic and prognostic marker both in solid 
cancers [14, 15] and hematologic malignancies [16, 17]. 
However, due to the possible cardiac side effects 
(lengthening of the electrocardiographic (ECG) QT interval 
and triggering of ventricular arrhythmia) that hERG1 
blockade may produce, this channel is generally considered 
an undesirable pharmacologic target [14, 18]. Therefore, 
many precautions must be taken when designing tools 
to target hERG1 in cancer, in order to avoid potentially 
harmful cardiac effects. To recognize hERG1 in normal 
and cancer tissues, we developed a unique anti-hERG1 
monoclonal antibody (hERG1-mAb) which recognizes 
an extracellular epitope (the S5-P loop) of the channel 
protein and hence can be used both on live and fixed cells 
without permeabilization [19]. However, the hERG1-mAb 
cannot be applied for in vivo cancer imaging, due to its 
large dimension and long half-life [20], which could impair 
tumor penetration and, conversely, facilitate the binding to 
the heart, i.e. the tissue where hERG1 is physiologically 
expressed. 
To exploit hERG1 as a novel target for in vivo 
molecular imaging, we generated and characterized 
smaller size antibody fragments in the scFv format, with 
the aim of obtaining the proof of concept for their further 
use as a molecular tool for in vivo cancer imaging.
RESULTS 
Generation of the scFv-hERG1 
The scFv-hERG1 was generated cloning the two 
variable heavy (VH) and light (VL) domains, amplified from 
the hERG1-mAb into the pCR-Blunt vector, following 
the procedure described in [21]. The DNA obtained from 
several E. coli positive colonies was sequenced and the 
most common VH and VL sequences were chosen (see 
Materials and Methods). VH and VL were then sequentially 
cloned into the pHenIX phagemid, which contains the 
sequence for the peptide linker necessary to join the 
carboxyl terminus of VH to the amino terminus of VL, and 
hence allows the proper assembly of the scFv-hERG1 
encoding cassette. The nucleotide sequence of this cassette 
is in Supplementary Figure 1, whereas the resulting amino 
acid sequence, obtained through the ExPASy translation 
tool, is shown in Figure 1A. The scFv-hERG1 expression 
cassette was then moved from pHenIX into pPIC9K and 
used to transform the GS115 P. pastoris yeast strain through 
the spheroplasting technique. We then chose the clone 
(G3) which showed the highest expression level of the 
protein after 72 hours of culture (Supplementary Figure 2A 
and 2B). The scFv-hERG1 antibody purified from scaled 
up (one liter) cultures was analyzed through SDS-PAGE 
and Coomassie Brilliant Blue staining (Figure 1B). The 
concentration of pooled fractions (Fr.) 11–14 was 0.050 
mg/ml, with a total amount of 100 μg. Size-exclusion 
chromatography (SEC) (Figure 1D) showed the presence 
of several peaks in the chromatogram: in particular, peaks 
1 and 3 indicated the presence of aggregated and degraded 
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proteins, respectively, in addition to the monomeric 
form, witnessed by peak 2 (see the gel in Supplementary 
Figure 3). The presence of aggregates and degradation 
products indicates instability of the scFv antibody 
molecule, possibly explaining the low protein yield 
obtained from this scFv-hERG1 preparation.
Production of a mutagenized scFv-hERG1
Since the instability and low protein yield of 
the “native” scFv-hERG1 could hinder further scaled 
up production and in vivo applications, we looked 
for strategies to improve the stability and yield of the 
antibody. From in silico analysis, we noticed the presence 
of a Phenylalanine (Phe) residue in position 92 of the VH 
sequence, between Framework 3 and CDR3, as resulted 
from the Kabat numbering scheme. This position often 
exhibits a conserved Cysteine (Cys) residue, crucial for 
the formation of a disulfide bond. Therefore, we decided 
to change the Phe into a Cys residue (see the arrow in 
Figure 1A), through site-directed mutagenesis. The T 
nucleotide in position 284, within the TTT codon, was 
substituted with a G, hence generating a TGT codon. The 
mutagenized construct, which carries the proper 284T>G 
mutation (Supplementary Figure 4), and therefore a Cys in 
position 92, was used to transform GS115 P. pastoris host 
yeast strain. We then chose the best (D8) scFv-hERG1-
Cys expressing clone (Supplementary Figure 5). SDS-
PAGE and Coomassie Brilliant Blue staining analysis of 
larger-scale cultures showed neat and evident bands in 
Fr. 12–14 (Figure 1C). A single, net and high peak, at the 
proper elution time was evident in the SEC chromatogram 
(Figure 1E). Overall the scFv-hERG1-Cys antibody shows 
good purity and stability. Consistently, the total amount of 
scFv-hERG1-Cys obtained from one liter of yeast culture 
was 1 mg, significantly higher compared to that obtained 
from the “native” scFv-hERG1. 
Evaluation of antigen affinity of the “native” and 
mutagenized scFv-hERG1
The immunoreactivity of both “native” scFv-hERG1 
and mutagenized scFv-hERG1-Cys was first tested 
through a sandwich ELISA assay, using the immobilized 
S5-Pore peptide as antigen. Figure 2A shows the results, 
expressed as Optical Density (O.D.). Both antibodies 
recognized the antigen in a dose-dependent manner, with 
a roughly two-fold higher binding of the scFv-hERG1-
Cys compared to the “native” scFv-hERG1. Figure 2A 
also shows the O.D. values obtained with 1 μg of the 
mAb-hERG1 from which the scFv antibody was 
generated, as well as with an Alexa-488 labelled scFv-
hERG1-Cys, that was used for further experiments, and is 
commented below. 
Overall, the mutagenized scFv-hERG1-Cys 
displayed higher binding capacity towards the antigenic 
peptide, compared to the “native” scFv-hERG1. We 
deepened the binding properties and affinity of the two 
scFv antibodies by Surface Plasmon Resonance (SPR). 
The intact mAb-hERG1 was analyzed for comparison. 
The binding responses of antibodies, flowed over the 
immobilized S5-Pore peptide at different concentrations, 
were recorded in sensorgrams (Figure 2B–2D) and 
experimental values were fitted to kinetic models (Table 
1). High quality fittings, as indicated by a residual χ2 
values < 2%, were obtained for both scFv antibodies, 
although with different kinetics. The best fitting for the 
“native” scFv-hERG1 was obtained by applying the 
“1:1 binding model”, whereas for the scFv-hERG1-Cys 
the “two-state reaction model” gave the best result. This 
suggests that the two scFv antibodies have different 
modes of interaction with the antigen (see Discussion). 
The KD value of the scFv-hERG1-Cys turned out to be 
lower compared to the “native” scFv-hERG1 (62 nM 
vs 318 nM, respectively) and closer to that of the intact 
mAb-hERG1 (16 nM) (Table 1). This value is the result 
of faster dissociation (lower Koff) and slower association 
(higher Kon) rates. This is also evident from the trend of 
the curves. Moreover, the Resonance Unit (RU) turned 
out to be 1021 for scFv-hERG1-Cys and 501.1 for the 
“native” scFv-hERG1. Overall the scFv-hERG1-Cys 
shows a much higher affinity for the antigen compared 
to the “native” scFv-hERG1. Finally, we used the 
SWISS-MODEL homology-modeling server to generate 
the 3D structure of the two scFv fragments. Both scFv 
antibodies showed correct core folding with very little 
conformational differences in the region carrying the 
mutation. Careful analysis of electrostatic surface potential 
and hydrophobicity did not indicate large differences 
between the two scFvs, other than in the loop and linker 
regions (Figure 2E and Supplementary Figure 6). 
In conclusion, the mutagenized scFv-hERG1-Cys 
displayed higher stability, purity and affinity towards the 
raising peptide, compared to the “native” scFv-hERG1, 
and was hence chosen for further characterizations, both 
in vitro and in vivo. 
Characterization of scFv-hERG1-Cys 
immunoreactivity
The immunoreactivity of the scFv-hERG1-Cys was 
first tested, through immunofluorescence (IF), towards the 
native hERG1 protein expressed on the plasma membrane 
of either normal or cancer cells. Both hERG1- and Mock- 
(as negative controls) transfected HEK 293 cells (HEK-
hERG1 and HEK-Mock, respectively) were used to this 
purpose. We performed both indirect IF (I. IF) on fixed 
cells and direct IF (D. IF), on either fixed or live cells, 
employing an Alexa 488-conjugated scFv-hERG1-Cys. 
Representative pictures are in Figure 3A–3C, along with 
densitometric analyses. The scFv-hERG1-Cys antibody 
specifically recognized the native antigen, being the signal 
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Figure 1: Biochemical characterization of scFv-hERG1 and scFv-hERG1-Cys antibodies. (A) Amino acid sequence of the 
scFv-hERG1-encoding cassette. The CDRs of the heavy and light chain, identified according to the Kabat scheme through the ANARCI 
software, are highlighted in green; the glycine-serine linker region is in bold. The arrow indicates the F (Phenylalanine) amino acid in 
position 92 (red), which was replaced by a C (Cystein), as reported in the line above. SDS-PAGE and Coomassie Brilliant blue staining 
performed on different fractions (Fr.) obtained after AKTA purification of scFv-hERG1 (B) and scFv-hERG1-Cys (C). After dialysis using 
Slide-A-Lyzer™ Dialysis Cassettes (Thermo Fisher, Massachusetts, USA) against PBS, scFv protein absorbance was measured at 280 nm 
and the Lambert-Beer equation was applied for antibody quantification. Size-Exclusion Chromatography (SEC) of scFv-hERG1 (D) and 
scFv-hERG1-Cys (E). According to the column used (Superdex 75, Ge Healthcare), proteins with a molecular weight around 30 KDa, 
such as scFv, should have a retention time of roughly 24–25 min. For the scFV-hERG1, the first peak, arbitrarily labelled as 1, corresponds 
to a retention time of 15 min and represents the aggregated form of the antibody; the second peak, arbitrarily labelled as 2, corresponds to 
a retention time of 24 min, and represents the scFv antibody; the third peak, arbitrarily labelled as 3, corresponds to 30–35 min retention 
time, and represents the degraded form of the protein. For the scFv-hERG1-Cys, a single peak is visible with retention time of nearly 
24 min, corresponding to what expected for a scFv molecule.
Oncotarget34976www.oncotarget.com
Figure 2: Antigen affinity and 3D structure modeling of scFv-hERG1 and scFv-hERG1-Cys antibodies. (A) ELISA assay 
performed using the S5-Pore peptide (sequence: EQPHMDSRIGWLHN) as coating antigen and testing different amounts (from 0.1 to 10 μg) 
of scFv-hERG1 and scFv-hERG1-Cys antibodies. The scFv-hERG1-Cys-Alexa488 antibody was tested at 1 μg. As a control, 1 μg of the 
full length mAb-hERG1 antibody was used. In case the ELISA assay is performed using mAb-hERG1, the procedure differs, as the 2 h 
incubation with the monoclonal antibody is followed by the revealing using secondary peroxidate anti-mouse antibody (no intermediate 
incubation with anti-tag antibodies, e.g. anti-His, occurs). Values are expressed as OD450 and are means ± SEM of two independent 
experiments. Sensograms showing the results from SPR (Surface Plasmon Resonance) analysis at different concentrations of the scFv-
hERG1 (B) and the scFv-hERG1-Cys (C) and hERG1-mAb (D) antibodies: violet 2.5 μg/mL, green 5 μg/mL, red 10 μg/mL, grey 
20 μg/mL, and blue 40 μg/mL. (E) Modeled three dimension structure of the scFv-hERG1 (indicated as scFv-Phe in blue) and 
scFv-hERG1-Cys (indicated as scFv-Cys in green) through the SwissModel Expasy modeling tool. The Phe and Cys residues involved in 
disulfide bond formation are indicated in red and yellow, respectively.
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significantly higher in HEK-hERG1 cells compared to 
HEK-Mock cells in all the experimental conditions. The 
good signals obtained with D-IF indicate that the antibody 
maintained the capacity of recognizing the antigen even 
after direct conjugation with the fluorophore, confirming 
the ELISA assay in Figure 2A. 
We then tested the immunoreactivity of the Alexa 
488-labeled scFv-hERG1-Cys on cancer cells, which 
express the hERG1 protein at high levels [9]. Figure 
3D shows data obtained with the Pancreatic Ductal 
Adenocarcinoma (PDAC) cell line PANC-1: a clear 
signal is evident at the plasma membrane level, with no 
evident diffused fluorescence due to unspecific Alexa 488 
binding. The Alexa 488-conjugated scFv-hERG1-Cys was 
also tested in PANC-1 cells cultured in 3D as spheroids 
[22]. We detected a high and clear signal, in all the images 
taken at different Z planes (top, medium and bottom) 
(Figure 3E), indicating a good penetration of the antibody 
into the cellular mass, better than the intact mAb-hERG1 
(Supplementary Figure 7). 
Characterization of scFv-hERG1-Cys: effects on 
cell viability
We then analyzed the effects of the scFv-hERG1-
Cys on cell viability: the antibody, used at either 10 or 
20 μg/ml, had no effects on the viability of wild type HEK 
293 cells, that do not express hERG1, neither after 24 or 
48 hours (Figure 4A). Furthermore, the higher dose of the 
scFv (20 μg/ml) did not affect the size and morphology 
of HEK 293 spheroids up to 72 hours (Figure 4B). On 
the contrary, scFv-hERG1-Cys added for 24 hours to 
HEK 293 hERG1 cells, which over-express hERG1, or 
to different cancer cell lines (triple negative breast cancer 
cell line, MDA-MB231, pancreatic ductal adenocarcinoma 
cell lines, PANC-1 and MIAPaCa-2, colorectal cancer cell 
line, HCT-116) endowed with high endogenous hERG1 
expression, significantly decreased cell viability (Figure 
4C). Consistently, longer incubations (up to 72 hours) 
significantly reduced spheroid volume of both HEK-
hERG1 (Supplementary Figure 8) and cancer cells. Data 
relative to MIAPaCa2 are in Figure 4D. 
Overall, while the scFv-hERG1-Cys has no effects 
on vitality of normal cells, it efficiently binds and exerts 
functional activities (decrease of cell vitality and growth 
rate) on hERG1 expressing tumor cells.
Serum stability and pharmacokinetics of the 
scFv-hERG1-Cys
The serum stability of the scFv-hERG1-Cys was 
then assessed to determine whether it is stable against 
proteolytic activities. The antibody was incubated at 37° C 
in mouse serum up to 96 hours and its concentration was 
determined through a sandwich ELISA assay. After 96 
hours, roughly 80% of the original antibody was present 
(Figure 5A), demonstrating that the scFv-hERG1-Cys is 
relatively stable in serum.
The pharmacokinetic (PK) properties of scFv-
hERG1-Cys were studied after intravenous (i.v.) injection 
into immunodeficient nude mice, i.e. the same strain 
used for testing the Alexa-labelled scFv antibody in 
optical imaging (see below). The protein was injected at 
160 μg/mouse and the plasma concentration was 
determined at different time points by a sandwich ELISA 
assay. The scFv-hERG1-Cys showed a characteristic two-
phase pharmacokinetic behavior, with a rapid distribution 
phase and a longer elimination phase (Figure 5B). The half-
life of the elimination phase turned out to be 3.1 hours. 
In vivo optical imaging 
The suitability of the scFv-hERG1-Cys for imaging 
applications was then analyzed. To this purpose, 10 and 
20 μg of an Alexa 750 conjugated scFv-hERG1-Cys 
were injected i.v. into immunodeficient nude mice, and 
the distribution of the labelled scFv was determined. 
To this purpose, we collected NIR images at different 
time points during the distribution phase, i.e. between 5 
and 60 minutes (see also Figure 5B). A clear and broad 
fluorescent signal was visible 5 and 10 minutes after 
injection, with high ROI (region of interest) values 
(Table 2), which started to decay at 60 minutes. A low 
signal remained evident in the lower abdominal area, 
very likely corresponding to kidney and bladder, 24 hours 
Table 1: Parameters derived from SPR analysis for the scFv-hERG1, scFv-hERG1-Cys and mAb-hERG1
Concentration Kon  (1/Ms)
Koff  
(1/s)
Ka2 
(1/s)
Kd2  
(1/s) KD (M)
R max 
(Ru)
Chi2 
(Ru2) U-value
scFv-hERG1 2.06E+04 6.55E–04 3.18E–07 501.1 7.96 1
scFv-hERG1-Cys 1.46E+05 8.07E–02 6.40E–03 8.07E–04 6.18E–08 4.1 N/A
mAb-hERG1 1.595E+6 2.584E–02 1.621E–8 109.3 1.85 10.00 
Values deriving from the SPR analysis related to Kon (1/Ms), Koff (1/s), Ka2 (1/s), KD (M), R max (RU), Chi
2 (Ru2), 
U-value. The SPR angle change is reported as resonance units (RU), where 1000 RU correspond to an angle change of ~ 
0.1º. If the added molecule does not bind to a target or receptor, the SPR angle change in the sample and reference flow cells 
will be the same, and, after subtraction, will give a zero net RU response that indicates no binding occurred.
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Figure 3: Immunofluorescence with scFv-hERG1-Cys. (A) Indirect immunofluorescence (I-IF) on fixed HEK-Mock and HEK-
hERG1 cells. Representative of 3 independent experiments performed in each cell line; the corresponding densitometric results are given 
in the bar graph on the right. Each image is representative of eight total images per experimental condition, analyzing ten cells per 
each. P values were calculated in respect to HEK-Mock cells using the Student’s t test, p < 0,05. (B) Direct immunofluorescence (D-IF) 
on fixed HEK-Mock and HEK-hERG1 cells using the scFv-hERG1-Cys-Alexa488. Representative of three independent experiments 
performed in each cell line; the corresponding densitometric results are given in the bar graph on the right. and the values obtained from the 
densitometric analyses of eight different images, considering ten cells each, P < 0,05 values were calculated in respect to HEK-Mock cells 
using the Student’s t test. (C) Direct immunofluorescence (D-IF) on live HEK-Mock and HEK-hERG1 cells using the scFv-hERG1-Cys-
Alexa488. Representative of three independent experiments performed in each cell line; the corresponding densitometric results are given 
in the bar graph. Brightfield images are reported in the insets. P values were calculated in respect to HEK-Mock cells using the Student’s 
t test, p < 0,05. Bar = 100 µm. (D) Direct immunofluorescence (D-IF) on fixed PANC-1 cells cultured in 2D using the scFv-hERG1-Cys-
Alexa488. The picture labelled as “CTR” represents cells incubated with only the secondary antibody. Representative of three independent 
experiments. Bar = 100 μm. (E) Direct immunofluorescence (D-IF) on fixed PANC-1 cells cultured in 3D as spheroids, using the scFv-
hERG1-Cys-Alexa488. TOP, MEDIUM and BOTTOM sections of the spheroids are shown. The picture labelled as “CTR” represents 
cells incubated with only the secondary antibody. Representative of 3 independent experiments. Bar = 200 μm (first and third field); 
Bar = 100 μm (second field). 
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after antibody injection, in mice treated with the higher 
(20 μg) antibody dose. At the same time point, no signal 
was evident in the mouse injected with the lower (10 μg) 
antibody dose (Figure 5C). At 24 hours the main organs 
were explanted and NIR signals evaluated: no NIR 
signal could be detected in explanted organs, except a 
scanty signal in the kidneys (Figure 5D). Neither signs of 
suffering were observed in the injected mice, during their 
monitoring for 10 days after inoculum, nor evident organ 
toxicity were detected at the sacrifice (Supplementary 
Figure 9). In particular, and most importantly, the scFv-
hERG1-Cys had no gross effects on ECG parameters, in 
particular on QT interval values (Figure 5E and related 
legend), as well as on the morphology or cardiac myocytes 
(Figure 5F).
Hence, we decided to use the higher (20 μg/mouse) 
dose of the Alexa-labelled scFv-hERG1-Cys antibody 
for testing its ability to bind hERG1 in a cancer tissue 
in vivo. To this purpose, we used an orthotopic PDAC 
mouse model (i.e. immunodeficient nude mice injected 
with MIAPaCa-2 cells in the pancreas as in [20]). Forty-
five days after tumor-cell injection, when a big tumor 
Figure 4: Effects of scFv-hERG1-Cys antibody on cell vitality of normal and cancer cells. (A) Effects of the scFv-hERG1-
Cys on cell viability of HEK 293 cells. Cell viability was assessed by the Trypan blue exclusion test after 24 h and 48 h of treatment with 
10 and 20 μg/ml of the antibody. Values are expressed as percentage of viable cells and are means ± SEM of four independent experiments. 
(B) Effect of the scFv-hERG1-Cys (20 μg/ml) on the growth of HEK 293 cells cultured as spheroids. Black symbols: control; white symbols: 
scFv-treated spheroids. Spheroids in control conditions and after 72 h treatment with scFv-hERG1-Cys are shown in the inset on the top. 
(C) Effects of scFv-hERG1-Cys on cell viability of HEK 293-hERG1 cells and different cancer cell lines (MDA-MB231, MiaPaCa-2 and 
PANC-1). Cell viability was assessed by the Trypan blue exclusion test after 24 h of treatment with 10 (grey bars) and 20 (white bars) 
μg/ml of the antibody. Values are expressed as percentage of viable cells and are means ± SEM of three independent experiments. (D) 
Effect of the scFv-hERG1-Cys (20 μg/ml) on growth of Mia-Paca 2 cells cultured in 3D as spheroids. Black symbols: controls; white 
symbols: scFv-treated spheroids. Spheroids in control conditions and after 72 h treatment with scFv-hERG1-Cys are shown in the inset 
on the top. Statistical analysis was performed applying Bonferroni test: p values < 0,05 were considered significative (**); p values < 0,01 
were considered highly significative (***). 
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Figure 5: In vivo characterization of scFv-hERG1-Cys antibody in healthy mice. (A) Serum stability of scFv-hERG1-Cys. 
Antibody concentration was determined by sandwich ELISA at different time points and is expressed as nanomolar concentration of the 
antibody. Values are means ± SD of two separate experiments. (B) Pharmacokinetics of scFv-hERG1-Cys. Immunodeficient nu/nu mice 
were injected i.v. with 160 μg of the antibody. Plasma was collected by tail vein puncture 5, 15, 30 min and 1, 2, 6, 24 and 48 h after scFv 
injection and the antibody concentration was determined by sandwich ELISA. Values are means ± SD of data collected in two different 
injected mice. (C) In vivo imaging of Alexa 750 labelled scFv-hERG1-Cys in healthy mice. Each panel shows the fluorescent signal in 
a mouse treated with scFv-hERG1Cys antibody conjugated with Alexa750 compared to a control mouse treated with PBS solution. Two 
mice were injected i.v. with 20 μg of antibodies, while one animal was injected with 10 μg. The fluorescent signal of the labeled scFv, 
was detected at different time points (5, 30, 60 minutes and 24 hours) from the administration. (D) Representative pictures of fluorescence 
analysis on dissected organs have been reported (pancreas, liver, kidneys and heart) collected after 24 hours from the injection of the scFv 
antibody. No fluorescent signal was detected, except for the kidneys, which showed a very weak fluorescent signal. Autofluorescence was 
subtracted based on the signal relative to WT non-injected mouse (Control). (E) ECG of a Control mice (upper panel) and a mouse treated 
with 20 μg of scFv (lower panel). The non-torsadogenic effect of the scDb was evalued considering no alterations were found either in 
the ECG trace and on ECG (Control mouse: QT interval = 34 ms, bpm = 380, QTc = 86. Treated mouse: QT interval = 36 ms; bpm = 372, 
QTc = 90 ms). No significant cardiac alterations were present. (F) Representative images of H&E (Hematoxylin and eosin) staining 
performed on heart sections deriving from immunodeficient nude mice injected with scFv-hERG1-Cys-Alexa750 antibody showing no 
evident signs of citotoxicity. Left panels, Control. Right panels. Section derived from mice injected with scFv-hERG1-Cys-Alexa750. 
Scale bars, left panels, 100 μm. Scale bars, right panels, 50 μm.
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mass inside the pancreas and many metastatic foci were 
present in the liver ([20] and Supplementary Figure 10), 
the Alexa 750 conjugated scFv-hERG1-Cys was injected 
i.v. and NIR images collected. A significant fluorescent 
signal was already detected 5 min after antibody injection, 
reaching an overall maximum level between 30 and 60 
minutes (Figure 6A). The signal was evident especially in 
the upper abdominal area, with ROI values significantly 
higher than those obtained, in the same area, in healthy 
mice (Table 3A). On the contrary, the signal in the lower 
abdominal area was roughly similar in PDAC and healthy 
mice. Sixty minutes after antibody injection, mice were 
sacrificed, the principal organs (liver, heart and pancreas) 
were collected and ex vivo NIR imaging measurements 
were performed. A clear fluorescent signal was detected 
in the tumor masses within the pancreas and in the 
metastases within the liver of mice treated with the scFv-
hERG1-Cys-Alexa750 antibody, compared to control 
mice. Lower signals were detected in the kidney, the 
main protein excretory organ, in injected mice, whereas 
no signal could be detected in the heart of both injected 
and not injected mice (Figure 6B). ROI values allowed 
to calculate the tumor-to-organ ratio of the labelled scFv 
antibody (Table 3B). 
Overall, the Alexa750-conjugated scFv-hERG1-Cys 
antibody is capable of reaching its target (i.e. the hERG1 
protein overexpressed in PDAC cells) and is retained in 
the tumor masses for enough time to allow its detection by 
NIR imaging techniques. 
DISCUSSION 
Molecular imaging can be used for the detection and 
staging of primary tumors, as well as for post treatment 
follow up of cancer patients. The major limitation of 
molecular imaging is the lack of specificity of most of 
the probes commonly applied. Hence, the development 
of imaging agents with higher binding capacity and 
selectivity to cancer is of great importance. Antibody-
based molecular imaging would be most suitable for 
this purpose, provided that tools with retained affinity, 
improved pharmacokinetics and high tumor-to-organ 
contrast ratios are developed. Smaller molecules, such as 
antibodies in the single chain format, scFv, are optimal 
candidates to fit such requirements [1–5]. In the present 
study we generated a single chain antibody (scFv) against 
a novel cancer biomarker (i.e. the hERG1 potassium 
channel) and provide a preliminary proof of concept 
that it has the appropriate features (easy production 
protocols, good stability and immunoreactivity, favourable 
pharmacokinetic and tumor-to-organ ratios in vivo) to be 
exploited for in vivo cancer diagnostics in the near future. 
The generation of high affinity antibodies from 
libraries is often difficult [22], hence we used a hybridoma 
cell line secreting relevant monoclonal antibodies (mAb) 
as the starting point for recombinant antibody work. The 
scFv we generated was in fact derived from the cloned 
VH and VL regions of an anti hERG1-mAb we produced 
in the past [18]. This “native” scFv-hERG1 suffered from 
a very low yield, that we traced back to the formation of 
aggregates as a result of instability of the antibody. The 
deduced amino acid sequence of the cloned scFv showed 
a Phe residue in position 92 of the VH domain, a site 
that usually contains a conserved Cys residue, usually 
involved in the formation of a disulfide bond between 
the b- and f- β strands of the immunoglobulin domain, 
with the corresponding Cys in position 22. Such disulfide 
bond is quite conserved in antibodies and does not appear 
necessary for proper function of antibodies while it 
confers stability to the molecule [23]. Only a few natural 
antibodies have been described, in which the disulfide 
bridge in the VH domain is lacking, because of the missing 
of either the 22 or 92 Cys residues [24]. In particular, 
the anti-ABPC48 antibody, although lacking the Cys in 
position 92 [25], maintains it functionality beacuse the 
Cys residue is replaced by a strong hydrophobic residue, 
Tyrosine [26], which preserves the hydrophobic core 
[27] and hence antibody performances. Similarly, in our 
“native” scFv antibody, a hydrophobic aminoacid replaces 
the Cys residue in position 92. This substitution likely 
occurs also in the natural hERG1-mAb (see the sequences 
of the pool of cloned VHs in Supplementary Figure 11. 
Consistent with what occurs in the anti-ABPC48 antibody, 
the natural hERG1-mAb shows good performances and 
affinity constants (low KD: 16 nM), while the scFv derived 
Table 2: ROI values obtained in healthy mice (n = 3) after i.v. of scFv-hERG1-CysAlexa750 at 5, 10, 60 min, 24 h. 
Values are normalized on controls
scFv-hERG1-Cys 
Alexa750 (1)
cpm/cm2
20 µg
scFv-hERG1-Cys
Alexa750 (2)
cpm/cm2
20 µg
scFv-hERG1-Cys
Alexa750 (3)
cpm/cm2
10 µg
5 min 766.6 766.6 115
10 min 683.3 683.3 158.3
60 min 316.6 550 233.3
24 h 51.6 53.3 25
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from it (the “native” scFv-hERG1) is unstable and shows 
a decreased affinity (higher KD, see Table 1). This is an 
expected finding, due to the univalency of the scFv [28]. 
On the contrary, the mutagenesis procedure we applied 
was capable to generate a single chain antibody, the scFv-
hERG1-Cys, with advantageous affinity constants, closer 
to those of the bivalent monoclonal antibody (KD 62 nM). 
In addition, the mutagenized scFv was more stable, without 
aggregates or degraded forms (Figure 1E), and hence 
with higher manufacturing performances. Furthermore, 
as derived from the sensorgrams in Figure  2B and 2C 
and the related fitting models, the two scFv antibodies 
display different kinetics, although both with high quality 
fitting, as indicated by low χ2 values. The different kinetics 
suggests that the two scFv antibodies have different modes 
of interaction with the antigen. In particular, the scFv-
hERG1-Cys displayed a more complex kinetics, fitted 
through the “two-state reaction model”, which suggests 
a possible structural rearrangement of the “antibody-
antigen” complex. However, a deeper understanding of 
Figure 6: In vivo distribution of the scFv-hERG1-Cys-Alexa750 antibody in a pancreatic tumor bearing mice. (A) 
scFv-hERG1-D8Cys-Alexa750 uptake and retention of scFv-hERG1-D8Cys-Alexa750 in a MIAPaCa-2-nu/nu mice model of PDA. Mice 
were administered through tail vein injection with 6.5 μg of scFv-hERG1-D8Cys-Alexa750 antibody. Representative pictures of mice i.v. 
injected with the labelled antibody (left) have been compared with control mice (right). Fluorescence intensity in the abdominal area, the 
site proximal to tumor has been analyzed. ROI values are reported in Table 3A. (B) Representative pictures of fluorescence analysis on 
dissected organs have been reported. Pancreas showed a clear fluorescent signal for the organ treated with the scFv-Alexa750 antibody 
while hearts did not show fluorescent signal in either the antibody treated mouse, as well as in the control mouse. Autofluorescence was 
subtracted based on the signal relative to WT non-injected mouse (Control).
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such possible conformational changes which might occur 
after the scFv binds to its antigen is outside the scope 
of this study. For our purposes, the finding of KD values 
more favorable for the scFv-hERG1-Cys represents the 
cornerstone for further antibody characterizations. Indeed, 
the mutagenized scFv-hERG1-Cys also showed good 
performances when tested in living systems. First of all, it 
showed a good labelling signal in hERG1-expressing cells, 
either hERG1-transfected HEK cells or cancer cells, which 
endogenously express the channel. In the latter cells, the 
engineered antibody was able to decrease cell proliferation 
(in 2D cultures) and the growth of 3D spheroids, further 
indicating its specificity for the hERG1 biomarker. On 
the contrary, it did not show any effect on the viability 
of normal cells in which hERG1 is not expressed, when 
cultured in vitro. More importantly, the scFv-hERG1-Cys 
did not show any acute or chronic toxicity when injected 
in healthy mice. In particular, we did not detect neither 
functional (ECG) or morphological (histology) cardiac 
alterations, and a very low accumulation of the 750 
Alexa-labelled scFv-hERG1-Cys in the heart. Although 
rodents are not the optimal models wherein to analyze 
potential side effects of hERG1 targeting, our results 
are encouraging proof of concepts to further proceed to 
regulatory analyses. Such good performances in vivo were 
also accompanied by a good stability in serum at 37° C, 
indicating resistance to protease activity, and by a rapid 
half-life, 3.1 hours, nor far from what commonly reported 
for scFv antibodies [29, 30]. Another good feature of our 
scFv was its good penetration into 3D spheroids, witnessed 
by a good labeling at any level of the cellular mass (Figure 
3E), accompanied by functional activities (reduction of 
spheroid growth) at concentrations comparable to those 
commonly used for these types of experiments [12]. The 
latter feature stresses the capability of the short antibody 
molecule to penetrate into cellular masses, a relevant 
prerequisite Overall, the above characteristics are relevant 
prerequisites for the applicability of the scFv-hERG1-Cys 
as an imaging tool to detect tumor masses in vivo. 
Furthermore, encouraging performances were 
shown by the Alexa-labelled scFv-hERG1-Cys antibodies. 
First of all, the labeling with an Alexa fluorophore did not 
alter the affinity (Figure 2A) and immunoreactivity of the 
antibody on cells (either fixed or live) (Figure 3). Good 
data also emerged from the Alexa 750-labelled antibody 
tested in vivo (Figures 5 and 6). In fact, the fluorescent 
antibody rapidly distributed in healthy mice, showed a fast 
clearance and did not accumulate into organs, including 
the heart (see the comments above). Furthermore, when 
used in an orthotopic model of PDAC cancer, we found a 
good accumulation into the abdominal area, corresponding 
to sites (pancreas and liver) with the presence of tumor 
masses. This was also confirmed by ex vivo data. What 
is more, the single chain antibody showed a very good 
tumor-to-tissue ratio since it was shown to accumulate 
within the neoplastic pancreas and the metastatic liver and 
no relevant fluorescent signal was detected in the heart. 
The tumor-to-organ ratios we obtained are compatible 
with what reported with other scFvs used for in vivo 
imaging applications [31–33] and better compared to 
whole antibody molecules [34].
Overall, our data indicate that the scFv-hERG1-Cys 
could be a good candidate as a diagnostic tool, with fast 
and less expensive production and purification protocols, 
suitable for in vivo imaging in those cancers in which 
hERG1 overexpression and its prognostic relevance has 
already been shown.
Table 3A: ROI values obtained in tumor-bearing mice (n = 2) after i.v. of scFv-hERG1-CysAlexa750 at 5, 10, 30, 60 min
scFv-hERG1-Cys
Alexa750 (1)
cpm/cm2
scFv-hERG1-Cys
Alexa750 (2)
cpm/cm2
5 min 13.3 5.7
10 min 333 233.3
30 min 581.6 250
60 min 500 310
Table 3B: ROI values obtained from tumor-bearing mice organs analysis ex-vivo
scFv-hERG1-Cys
Alexa750 (1)
cpm/cm2
scFv-hERG1-Cys
Alexa750 (2)
cpm/cm2
Tumor to organ 
ratio
Pancreas 60.3 1.9 105.5
Liver 17.6 30 25.3
Hear 24.3 27 1
Values are normalized on controls.
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MATERIALS AND METHODS 
Cloning of the heavy and light chains of the 
hERG1 mAb
The heavy and light chain cDNA of the hERG1-
mAb was PCR-amplified after reverse transcription 
of the total RNA extracted from A7 hybridoma using 
SuperScript® II Reverse Transcriptase, (Thermo Fisher, 
Massachusetts, USA), according to manufacturer’s 
instructions. 
According to Wang and colleagues [21], the VH region 
was amplified using five different degenerated forward 
primers that anneal to the framework 1 (FR1) of the variable 
domain (degH1 to degH5) and a reverse primer that anneals 
to the constant region of the immunoglobulin isotype of 
the hERG1 mAb, i.e. IgG2b. The VL region was amplified 
using a degenerated forward primer and a canonical reverse 
primer, both relative to the κ type light chain, degL(κ)_
forward and κ_reverse, respectively. The cDNA was 
amplified using Phusion® High-Fidelity DNA Polymerase 
(Finnzymes Reagents). The agarose gel showing VH and VL 
amplification is shown in Supplementary Figure 12 and the 
primers’ sequences are reported in Supplementary Table 1 
in the Supplementary Materials.
After electrophoresis gel separation and DNA 
purification, the two VH and VL PCR fragments, were 
independently cloned into pCR-Blunt (Invitrogen) vector 
following manufacturer’s instructions, and the resulting 
plasmids were used to transform DH5 α E. coli cells.
Colonies were screened to verify the presence of the 
insert, both by excising the insert through digestion with 
NotI (New England BioLabs, Massachusetts, USA) and 
by PCR amplification (using the primers reported in the 
Supplementary Table 1) of the extracted plasmid DNA. 
The extracted DNAs from eight colonies were sequenced 
through Automated DNA sequencing service (PRIMM) 
and the most common sequence was chosen. Some 
representative sequences obtained in pCR-Blunt vector 
are reported in Supplementary Figure 11.
Cloning into pHenIX expression vector 
VH and VL sequences were then cloned into the 
pHenIX phagemid, which contains the peptide linker 
sequence necessary to join the carboxy terminus of VH 
to the amino terminus of VL, thus allowing the proper 
assembly of the scFv antibody. First, appropriate restriction 
sites were added to the VH and VL sequences by PCR, using 
the primers reported in Supplementary Table 2.
After cloning into pHenIX phagemid, the proper 
orientation of the insert was verified through Sanger 
sequencing resulting in only one colony containing the 
VH-linker-VL sequence properly inserted and oriented (see 
Supplementary Figure 13).
Cloning of scFv in pPIC9K expression vector
To clone the scFv-hERG1 into the pPIC9K vector, 
suitable for protein expression in P. pastoris yeast cells, 
the scFv expression cassette in the pHenIX vector was 
amplified by PCR using primers introducing the FspI and 
AvrII restriction sites at 5′ and 3′ ends of the sequence, 
respectively (reported in Supplementary Table 3). 
Restriction sites were inserted using Phusion® High-
Fidelity DNA Polymerase (Finnzymes Reagents), with 
the following PCR cycling conditions: 94° C for 2 min, 
28 cycles of a three-step program (98° C for 30 sec; 
59° C for 30 sec and 72° C for 30 sec) followed by a final 
extension step of 72° C for 10 minutes. After separation 
of the PCR product through agarose gel electrophoresis, 
the band of the appropriate molecular weight (870 bp) 
was excised from the gel and purified using QIAquick 
PCR Purification Kit (QIAGEN, Hilden, Germany). The 
DNA was then cut with FspI and AvrII to allow its ligation 
into the pPIC9K vector that had been cut with Eco53KI 
and AvrII restriction enzymes (New England BioLabs, 
Massachusetts, USA).
scFv-hERG1 mutagenesis 
Mutagenesis was performed on the scFv-
hERG1 expression cassette cloned into pPIC9K using 
the QuikChange® XL Site-Directed Mutagenesis Kit 
(Stratagene, Agilent Technologies, California, USA), 
according to the manufacturer’s instructions, using the 
following primers (Primm Biotech): forward primer: GG
ATTCTGCAGTCTATTACTGTGCAACAGGTTGGGG
ACCTG; reverse primer: CAGGTCCCCAACCTGTTG
CACAGTAATAGACTGCAGAATCC. DH5α competent 
cells were transformed with the DNA obtained after the 
mutagenesis protocol and plasmid DNA extracted from 
different colonies was sequenced to verify the presence of 
the desired mutation. 
scFv expression in Pichia pastoris
The scFv construct in pPIC9K was linearized with 
SalI and used to transform the P. pastoris strain GS115 
using the spheroplasting technique. The Pichia Expression 
Kit (Thermo Fisher, Massachusetts, USA) protocol was 
followed. 
Purification using ÄKTA chromatography 
systems 
The purification of yeast supernatants (1 liter) 
obtained from scaled up cultures, was performed by 
Affinity Chromatography, using an ÄKTA Protein 
Purification System (Ge Healthcare Life Sciences, Illinois, 
USA) using a HisTrap HP 1 ml column (Ge Healthcare Life 
Sciences, Illinois, USA). Wash steps and equilibration were 
performed according to the manufacturer’s instructions, 
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using Wash buffer (20 mM sodium phosphate, 500 mM 
NaCl, pH 7.3). Elution was performed through a linear 
gradient of Elution buffer (20 mM sodium phosphate, 500 
mM NaCl, 500 mM imidazole, pH 7.3). Chromatogram 
analysis was accomplished using UNICORN 7.0 software.
Gel Filtration
Samples obtained from purification were dialyzed 
against 20 mM sodium phosphate, 150 mM NaCl, pH 
7.3 buffer using Slide-A-Lyzer™ Dialysis Cassettes 
(Thermo Fisher, Massachusetts, USA) and gel filtered, 
using Superdex 75 HR 10/30 (Ge Healthcare Life 
Sciences, Illinois, USA). According to the characteristics 
of the column (Superdex 75, Ge Healthcare Life Sciences, 
Illinois, USA), proteins with a molecular weight of around 
30 KDa, like scFv, should have a retention time of roughly 
24–25 minutes. Wash buffer composition was adjusted to 
optimize protocol conditions (20 mM sodium phosphate, 
150 mM NaCl, pH 7.3). Eluted solutions were analyzed 
through SDS-PAGE.
Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western 
blotting
SDS and Western Blot analysis were performed 
according to [16]. 
Sandwich ELISA assay 
Sandwich ELISA was performed following 
standard method, using anti-6xHis antibody (Abcam, 
Cambridge, UK) 1:250 in PBS + 3%BSA to reveal the 
scFv, followed by anti-mouse IgG-HRP conjugate (Sigma, 
Missouri, USA) 1:500 in PBS + 3%BSA, as described in 
[35]. In case the ELISA assay is performed using mAb-
hERG1, the procedure differs as the 2 h incubation with 
the monoclonal antibody is followed by the revealing 
using secondary peroxidate anti-mouse antibody (no 
intermediate incubation with anti-tag antibodies, e.g. anti-
His, occurs).
Pharmacokinetic analysis 
2 Balb/c mice have been injected with 160 μg of 
scFv-hERG1-Cys antibody and blood samples have been 
collected from the tail vein at 0, 5, 15, 30, 120, 360, 1440, 
2880 minutes after antibody injection. Each sample was 
spun at 12000 rpm for 5 minutes; the resulting plasma was 
stored at −80° C until analyzed. The plasma concentration 
of scFv-hERG1-Cys antibody was determined by 
sandwich ELISA, using anti-6xHis antibody (Abcam, 
Cambridge, UK) 1:250 in PBS + 3%BSA to reveal the 
scFv, followed by anti-mouse IgG-HRP conjugate (Sigma, 
Missouri, USA) 1:500 in PBS + 3%BSA. The half-lives 
for elimination phase were determined using Origin 
7.0 Software by fitting the last four data points into the 
first-order equation, T1/2 = (∆t/t1-t0)/∆C where (∆t/t1-
t0) represents the slope of the curve and ∆C represents 
the value corresponding to the half of the antibody 
concentration at t1.
Surface plasmon resonance analysis
The affinities of the scFv and mAb-hERG1 
antibodies were measured by the surface plasmon 
resonance (SPR) method, using a Biacore T100 and a 
Biacore T200 instrument, respectively (GE Healthcare, 
Illinois, USA). For the scFv analyses, the S5-Pore 
peptide was covalently immobilized to the flow cell of 
a carboxymethylated dextran CM5 sensor chip using an 
amine-coupling strategy. Successful immobilization was 
performed with 7 injections of 540 s each, 5 µl/min, in 
10 mM acetate buffer at pH 4.5. The two scFv were then 
flowed over immobilized S5-Pore peptide at different 
concentrations (2.5, 5, 10, 20, and 40 μg/ml), according 
to the following conditions: contact time, 120 sec; 
dissociation time, 600 sec; flow, 30 µl/min. Regeneration 
was performed using 100 mM Glycine, pH 2.5. MAb-
hERG1 was bound to a Protein G pre-coated CM5 
sensor chip to reach a level of immobilization of 7693 
relative units (RU). S5-Pore was then applied at different 
concentrations (10 nM, 50 nM, 100 nM, 500 nM) using the 
Single Cycle kinetics method to derive binding kinetics, 
according to the following conditions: contact time 30 s, 
dissociation time 120 s, flow 30 µl/min. Regeneration was 
performed using 100 mM Glycine, pH 1.7. Data analysis 
was performed using BIA Evaluation software v 3.1.
Cell culture
HEK-hERG1 cells, HEK-MOCK and PANC-1 cells 
were routinely cultured in bidimensional (2D), as described 
in detail in the Supplementary Materials. Mia Paca2 cells 
were cultured as in [20]. 3D cultures (spheroids) were 
performed following the protocol described in [22].
Immunofluorescence (IF)
HEK-hERG1 cells, HEK-MOCK and PANC-1 cells 
were routinely cultured in bidimensional (2D). Both direct 
and indirect IF were performed as in [15, 21]. Details are 
reported in the Supplementary Materials.
Cell viability assay
Cell viability was evaluated performing a Trypan 
blue assay. Briefly, cells were seeded in a 96-well plate 
at a density of 5 × 103 cells/well. The following day, 
the medium was replaced with 100 µl of fresh medium 
containing different concentrations of the scFv-hERG1-
Cys antibody (10 μg/ml and 20 μg/ml). After 24 hours 
and 48 hours incubation, cells were detached and viable 
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cells were counted. All the experiments were carried out 
in triplicate.
Antibody structure modelling
Antibody modeling was performed through the 
SWISS-MODEL (ExPASy) protein structure homology-
modelling server [36, 37]. We have not referred to a target 
model alignment. In fact, if the target-template sequence 
identity is lower than 40%, the alignment generally has 
gaps and needs manual intervention to minimize the 
number of misaligned residues
Antibody labelling with Alexa 488 and Alexa 750 
fluorophore
The scFv-hERG1Cys was conjugated with Alexa 
Fluor® 488 Microscale Protein Labeling Kit (Thermo 
Fisher Scientific, Massachusetts, USA), according to 
the indications in the protocol. We have calculated the 
DOL (Degree of Labelling) according manifacturer’s 
instructions and it turned out to be 2.2.
Conjugation with Alexa 750 (Thermo Fisher 
Scientific, Massachusetts, USA) was performed after 
adjusting the labelling protocol, as no commercial kits 
suitable for the labelling are available. To individuate 
the best labelling conditions, three different quantities 
of dye were used to react with 150 μg of scFv-hERG1-
Cys: condition 1–4 µl of Alexa Fluor® 750 NHS Ester; 
condition 2–8 µl of Alexa Fluor® 750 NHS Ester; 
condition 3–12 µl of Alexa Fluor® 750 NHS Ester. The 
scFv-hERG1-Cys at a concentration of 2 mg/ml in PBS 
solution and 0.1 M sodium bicarbonate buffer pH 8.3, was 
incubated 1 hour at 22° C in agitation with the different 
amount of Alexa Fluor® 750 NHS Ester (Succinimidyl 
Ester) (Thermo Fisher Scientific, Massachusetts, USA), 
resuspended in DMSO at 10 mg/ml. The reaction was 
blocked for 5 minutes in ice and the labelled protein was 
purified by size exclusion chromatography on a Sephadex 
G25 (Sigma, Missouri, USA) column equilibrated with 
PBS. The concentration of protein in the three conditions 
was initially calculated by the equation: 
protein concentation= Aprotein × protein m.w./∑protein
where Aprotein= A280–Amax× 0,04, with Amax 
(absorbance of dye at ≤max) determined at 749 nm and 
0,04 = contribution of the dye to the absorbance at A280 
(CF Alexa750 = 0,04).
Subsequently the degree of labelling (D.O.L., 
corresponding on the number of dye molecules present 
on the labelled protein) was calculated for the three 
conditions by the equation:
D.O.L.= (Amax × protein m.w.)/([proteina] × ∑dye) 
where ∑dye = 290000 cm
–1 M–1
D.O.L. for each condition resulted to be 1.48 
(condition 1), 2.17 (condition 2) and 4.25 (condition 3). 
One aliquot of proteins from each labelling condition 
was controlled on 15% SDS PAGE (Supplementary 
Figure 14) confirming the data obtained by D.O.L. 
calculation: for condition 1 is evident an increase 
of molecular weight of protein of 1300 g/mol (dye 
molecular weight), for condition 2 an increase 2600 
g/mol and and for condition 3 and increase of 5200 g/
mol. Since the condition 2 approximately presents the 
same D.O.L. obtained by labelling with Alexa Fluor® 
488 Microscale Protein Labeling Kit, it was chosen for 
in vivo experiments.
In vivo analysis
In vivo imaging: All experiments involving mice 
were approved by the Italian Ministry of Health. In vivo 
experiments were performed by the LIGEMA, a joint 
laboratory of University of Florence and Dival Toscana 
srl, at the Animal Facility of the University of Florence. 
Three six-week old, female immunodeficient Athymic 
Nude-Foxn1 nude mice were injected intravenously with 
50 µl (1 nm dye/mouse) of scFv-hERG1-Cys labeled with 
the fluorophore Alexa 750 and fluorescence was measured 
5, 10, 60 minutes and 24 hours after antibody injection. 
One control mouse was treated with sterile PBS solution. 
All the fluorescent emission spectra were measured 
using a Photon imager (Biospace Lab). The imager had a 
laser source for fluorescence excitation (λ = 679 nm), an 
emission filter (λ = 702 nm) for fluorescence detection, 
and a computer for data analysis.
The fluorescent signal of the fluorophore 
was detected with the optical imager PhotonImager 
(BiospaceLab); the set-up of the acquisitions was: FLI 
integration (shutter: 1000 ms, 4 s per frame) Fluorophore: 
Alexa 750, Excitation = 749 nm, Emission = 775 nm, 
Lens: diaphragm = 1.4 focus = 87.0% Aperture autopilot: 
yes Stage height: 440 mm Software version: 2.11.0. All 
the collected scans were elaborated with the software 
M3vision, in order to save the picture and quantificate the 
signal detected (in terms of ROI).
ECG measurements were performed using 
VevoLAZR-X imaging station and calculated with Vevo 
LAB Analysis Software. To analyze the mice ECG we 
used Vevo LAB software, measuring the time (ms) 
between the start of the Q wave and the end of the T wave, 
in order to assess the QT interval. The QTc interval was 
calculated using the Bazett formula. Subsequently, the 
ECG data (mV and ms) were extracted and the ECG curve 
was reproduced by using Origin software.
Mouse Model: the MIAPaCa-2 cell line was used 
for tumor cell implantation, as described in [20]. Cells 
were cultured in DMEM supplemented with L-glutamine 
(4 mM), 10% fetal bovine serum and Geneticin (G418) 
(2.4 mg/ml) (Gibco, Massachusetts, USA) at 37° C in a 
humidified atmosphere of 5% CO2. MIAPaCa-2-luc cells 
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were injected into the pancreas of nude mice and the 
animals were monitored (as described in [20]) and 45 days 
after the cell inoculum, mice were administered with scFv-
hERG1Cys-Alexa750 antibody.
Statistical analysis
Statistical analysis was performed applying Shapiro-
Wilk test and Bartlett test to assess data normality and 
homoscedasticity assumptions respectively. Associations 
between continuous variables and categorical variables 
were analyzed through Anova; subsequently, to determine 
pairwise statistical significance Tukey test (*p < 0,05) or 
Bonferroni test have been applied. p values < 0,05 were 
considered significative; p values < 0,01 were considered 
highly significative. 
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